Table 1 Patient Characteristics.
From: Comprehensive RNA-seq transcriptomic profiling in the malignant progression of gliomas
| Â | All Patients ( N =325) | |
|---|---|---|
Characteristics | No. | % |
Age classes | ||
 <18 | 3 | 0.92 |
 18–35 | 71 | 21.85 |
 36–39 | 51 | 15.69 |
 40–49 | 103 | 31.69 |
 50–59 | 61 | 18.77 |
 60–69 | 31 | 9.54 |
 ≥70 | 5 | 1.54 |
Sex | ||
 Male | 203 | 62.46 |
 Female | 122 | 37.54 |
WHO grade classes | ||
 Grade II | 109 | 33.54 |
 Grade III | 72 | 22.15 |
 Grade IV | 144 | 44.31 |
TCGA classes | ||
 Classical | 74 | 22.77 |
 Mesenchymal | 68 | 20.92 |
 Neural | 81 | 24.92 |
 Proneural | 102 | 31.39 |
Chemoradiotherapy | ||
 Radiotherapy plus other drugs | 8 | 2.46 |
 Radiotherapy plus temozolomide | 78 | 24.00 |
 Radiotherapy plus unknown drug | 64 | 19.69 |
 Chemotherapy with temozolomide alone | 12 | 3.69 |
 Chemotherapy with unknown drug alone | 14 | 4.31 |
 Radiotherapy alone | 87 | 26.77 |
 No data for radiotherapy plus temozolomide | 1 | 0.31 |
 Radiotherapy plus no data for chemotherapy | 2 | 0.62 |
 No data for chemoradiotherapy | 27 | 8.31 |
 No therapy | 32 | 9.84 |
Epilepsy therapy | ||
 Anti-epileptic | 85 | 26.15 |
 No therapy | 157 | 48.31 |
 No data | 83 | 25.54 |
